Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Sep 10, 2009

Premium

Title: microRNA and Methods for Inhibiting the Same

Number: 7,585,969

Filed: March 10, 2008

Lead Inventor: Markus Stoffel, Rockefeller University (Alnylam Pharmaceuticals)

“The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA,” the patent’s abstract states. “In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.”


Title: Method of Cancer Treatment Using siRNA Silencing

Number: 20090220582

Filed: June 15, 2006 PCT Filed: June 15, 2006

Inventor: Weiping Min, London Health Sciences Centre Research

The invention, the patent application’s abstract states, “is a method for the treatment of cancer involving tumor-derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.”


Title: Treatment, Diagnostic, and Method for Discovering Antagonist Using SPARC-Specific miRNAs

Number: 20090220589

Filed: March 2, 2009

Lead Inventor: Vuong Trieu, Abraxis BioScience

According to the patent application’s abstract, the invention comprises “miRNAs that regulate human SPARC and methods of use thereof. … Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, ds-miRNA, mature miRNA, or fragments of variants thereof that retain the biological activity of the mature miRNA; and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments, or variants thereof, or regulatory elements of the miRNA.”


Title: Composition for Suppressing the Expression of Fucosyltransferase

Number: 20090221065

Filed: March 2, 2007 PCT Filed: March 2, 2007

Lead Inventor: Akihiro Kondo, Osaka University (Takara Bio)

The invention, the patent application’s abstract states, comprises “a means for reducing the expression amount of a FUT8 gene, reducing the expression amount of a FUT8 protein, and/or reducing the expression amount of a product produced by the action of FUT8.”

Specifically, the application claims the use of a double-stranded RNA capable of inhibiting expression of a 1,6-fucosyltransferase in a cell.


Title: Microarray for Detecting and Quantifying microRNA

Number: 20090221435

Filed: Feb. 7, 2007 PCT Filed: Feb. 7, 2007

Lead Inventor: Scott Baskerville, Dharmacon (Thermo Fisher Scientific)

According to the patent application’s abstract, “a microarray can be configured for hybridizing with short nucleic acids, such as miRNA or siRNA, contained within a sample. Such a microarray includes a polynucleotide trap coupled to a substrate of a microarray site. The polynucleotide trap includes a probe that selectively hybridizes with short nucleic acid sequences, and a linker that is coupled to the substrate and configured to extend the probe from the substrate,” the abstract adds. “Additionally, the polynucleotide trap can include an enhancer that hybridizes with the linker in order to enhance functionality of the probe. The linker and/or enhancer are configured to inhibit the probe from interacting with the linker or substrate. This can include the linker and/or enhancer being configured to have a minimal secondary structure so as to present the probe region for hybridizing with the target polynucleotide and inhibit the linker region or probe region from interacting with the substrate.”


Title: Compositions and Methods for Therapy and Diagnosis of Cancer

Number: 20090221674

Filed: Dec. 7, 2006 PCT Filed: Dec. 7, 2006

Lead Inventor: Ugur Sahin, Ganymed Pharmaceuticals

The invention, the patent application’s abstract states, “is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies.”

The invention also includes “methods which make possible to assess and/or prognose the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer,” the abstract notes.


Title: Oligomeric Compounds and Compositions for the Use in Modulation of microRNAs

Number: 20090221685

Filed: Jan. 27, 2007 PCT Filed: Jan. 27, 2007

Lead Inventor: Christine Esau, Isis Pharmaceuticals

The patent application, its abstract states, claims “compounds, compositions, and methods … for modulating the levels [of] expression, processing, and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activity in a cell.”

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.